Autres langues Cynata Therapeutics Limited OTC Markets

Actions

CYYNF

AU000000CYP7

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:54:28 04/08/2026			Varia. 5j.	Varia. 1 janv.
0,008600 ^USD	+115,00%		-.--%	-94,27%

31/08	Cynata Therapeutics Limited publie ses résultats pour l'exercice clos le 30 juin 2026	CI
06/07	Cynata Therapeutics Limited met fin à son essai de phase 2 sur la maladie du greffon contre l'hôte et suspend ses activités externalisées	CI

Autres langues

31/08	Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2026
06/07	Cynata Therapeutics Limited Terminates Phase 2 Graft Versus Host Disease Trial and Outsourced Activities
06/07	Cynata Therapeutics Limited Enters into an R&D TI Loan Facility with a Commercial Lender
06/07	Cynata Therapeutics Limited Announces Management Resignations, Effective July 6, 2026
06/07	Cynata Therapeutics Limited Announces Resignation of Kilian Kelly as CEO, Effective July 6, 2026
19/06	Cynata Therapeutics' Failure to Meet Main Endpoints in Two Trials is 'Highly Disappointing Outcome,' Euroz Hartleys Says
17/06	Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results
03/06	Cynata Therapeutics Gets Positive European Opinion for Acute Graft Versus Host Disease Trial
29/05	Cynata Says WHO Selects Generic Name for Cymerus Mesenchymal Stem Cells
27/05	Cynata Therapeutics Says Results for Phase Three Drug Candidate Study for Knee Osteoarthritis Expected in June; Shares Rise 6%
11/05	Cynata Therapeutics' Upcoming Trial Readouts 'Most Significant Catalysts' in Years, Euroz Hartleys Says
04/05	Cynata Therapeutics Secures Commitments for AU$1.5 Million Share Placement; Shares Fall 4%
04/05	Cynata Therapeutics receives commitments for A$1.5 mln placement at A$0.25 per share
30/04	Cynata Therapeutics seeks trading halt pending announcement on proposed capital raising
30/03	Cynata Therapeutics Says Final Participant in Phase Two Acute Graft Versus Host Disease Drug Candidate Trial Completes Evaluation Period
09/03	Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys
26/02	Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2025
16/12	Cynata Therapeutics' Recruitment Completion for Acute Graft Versus Host Disease Clinical Trial Provides Reference for Results Timing, Euroz Hartleys Says
15/12	Cynata Completes Patient Enrollment in Phase 2 Trial of Acute Graft Versus Host Disease Drug Candidate; Shares Rise 6%
15/12	Cynata Therapeutics Limited Completes Patient Enrolment in Phase 2 aGvHD Clinical Trial
04/12	Cynata Therapeutics Receives Clearance to Proceed to Second Group in Phase 1/2 Kidney Transplant Trial; Shares Jump 10%
24/11	Cynata Therapeutics Completes Phase 3 SCUIpTOR Trial in Knee Osteoarthritis; Shares Up 6%
03/11	Cynata Therapeutics' Three Active Programs Expected to Deliver 'Major' Catalysts Over Next Quarters, Says Euroz Hartleys
28/08/25	Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2025
22/08/25	Cynata Therapeutics enters at-market subscription agreement with Acuity Capital